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Abstract
Objectives Calcineurin inhibitors (CNI) are approved for the treatment of
myasthenia gravis (MG) in Japan. However, the extent to which CNI have
been effective remains unclear. Here we report data regarding CNI use and
outcomes of MG.
Methods We evaluated 640 consecutive MG patients by a multicenter sur-
vey. Patients not receiving any immune treatment were excluded, and
cross-sectional and retrospective data of 515 patients receiving immune
treatment with (n = 312) or without (n = 203) CNI were analyzed.
Results Compared with patients treated without CNI, those treated with
CNI had a higher frequency of MG Foundation of America Class III–V and
higher severity disease at the worst clinical condition, and also had current
higher severity, worse quality of life and higher daily doses of prednisolone,
despite taking equivalent prednisolone dosages during the course of treat-
ment. Achieving a treatment target was less frequent in the group treated
with CNI. Onset age was not different between the two groups. Duration
before CNI use after starting corticosteroids was 4.4  6.3 years. Among
those treated with CNI, late-onset MG patients achieved a more favorable
current condition than did those with early-onset and thymoma-associated
MG, whereas there was no such difference without CNI treatment.
Conclusions CNI were given to severely ill MG patients with no attempt to
select those more likely to respond, and failed to exert a strong impact on
MG therapy. CNI should be given aggressively to patients with factors
known to enhance susceptibility to these drugs, such as higher age at onset
and early-stage disease.
Introduction
Myasthenia gravis (MG) is an autoimmune disease
mediated by antibodies against molecules in the neu-
romuscular junction, impairing neuromuscular trans-
mission.1 Pathogenic autoantibodies in MG are
generally anti-acetylcholine receptor antibodies
(AChR-Ab) that are detected in 80% of patients,
infrequently anti-muscle-specific receptor tyrosine
kinase antibodies (MuSK-Ab) in 2–3% or fairly infre-
quently anti-low-density lipoprotein receptor-related
protein 4 antibodies.1–5 Production of AChR-Ab in
B cells depends on AChR-specific T cells.6,7 Calcineu-
rin inhibitors (CNI), such as cyclosporine and tacroli-
mus, bind to different target molecules (cyclophilin
and FK-binding protein, respectively), but they inhi-
bit T-cell activation in the same way, through calci-
neurin inhibition.8–10 A considerable number of
reports have shown CNI efficacy against MG.11–17
Oral corticosteroids are still the most common
agent for long-term immunosuppressive treatment of
MG.2 As MG is a severe disease with a high mortal-
ity rate, the spread of oral corticosteroid use has led
to a non-lethal disease course for MG patients.18
© 2015 Japanese Society for Neuroimmunology 195
Clinical and Experimental Neuroimmunology 6 (2015) 195–200
Clinical & Experimental 
Neuroimmunology
However, many patients need to continue taking
oral corticosteroids for many years and are thus bur-
dened with associated side-effects, as the rate of MG
patients achieving full remission and no longer
requiring immune treatment is very low.4,19–22 The
frequency of patients achieving a treatment target of
favorable health-related quality of life (HRQOL) is
<50%.4,19 It is clear that treatment primarily with
oral corticosteroids does not actually ensure a favor-
able outcome.21
In Japan, CNI are approved for the treatment of
MG under the national health insurance system, and
are considered to be steroid-sparing and symptom-
reducing agents for MG. However, the extent to
which CNI exert a positive effect on improving
symptoms and HRQOL of MG remains unclear. We
have carried out a multicenter survey (Japan MG
registry) obtaining detailed clinical parameters from
>600 MG patients in order to clarify the condition of
these patients including HRQOL.3,4,19–21 In the pres-
ent report, we delineate actual CNI use and patient




The present study was carried out at 11 neurological
centers in Japan (Japan MG Registry Group).3,4,21
We evaluated adult patients with established MG
between April and July 2012. To avoid potential bias,
we enrolled consecutive patients at various stages of
illness over a short duration (4 months). The present
study required detailed information of each patient,
and 36 patients without full information or not pro-
viding written informed consent were excluded from
the total of 676 patients seen during the study per-
iod.3,4,21 Given that the purpose of this study was to
elucidate impacts of CNI on the immune treatment of
MG, we further excluded 125 patients who did not
receive any immune treatments during the course of
their disease. Ultimately, 515 MG patients provided
written informed consent and were subjected to
analysis. Clinical background data for the patients
treated with (n = 312, 61%) or without (n = 203,
39%) CNI are shown in Tables 1 and 2.
The study protocols were approved by the ethics
committees of each participating institution. Written
informed consent was obtained from all patients par-
ticipating in the study.
Diagnosis of MG was based on clinical findings
(fluctuating symptoms with easy fatigability and
recovery after rest) with amelioration of symptoms
after intravenous administration of anticholinester-
ase, decremental muscle response to a train of low-
frequency repetitive nerve stimuli of 3 Hz, or the
presence of AChR-Ab or MuSK-Ab. Single-fiber elec-
tromyography was not carried out routinely.
Clinical factors
Clinical factors shown in Tables 1 and 2 were evalu-
ated for each patient and subjected to analysis.
Severity was determined according to the MG Foun-
dation of America (MGFA) quantitative MG score
(QMG).23 For 413 of the 515 patients, QMG at the
worst clinical condition was obtained from medical
records. All patients completed the Japanese version
of the 15-item MG-specific QOL scale (MG-QOL15-
J).19 Current clinical status after treatment was cate-
gorized according to the MGFA post-intervention
status.23 Among categories of MGFA post-interven-
tion status, minimal manifestations (MM) or better
Table 1 Comparison of patients receiving immune treatments with and







Age (years) 58.5  16.8 57.0  16.4
Age at onset (years) 46.8  19.5 47.4  17.7
Time since onset (years) 11.8  10.7 9.8  9.0
Treatment with PSL (%) 100 90.4
Duration between onset and starting
immune treatments (years)
2.7  5.6 2.2  5.1
Duration before CNI use after starting
immune treatments (years)
– 4.4  6.3
Early-onset MG (%) 44.3 41.0
Late-onset MG (%) 37.4 32.4
Thymoma-associated MG (%) 18.2 26.6#
Thymectomy (%) 54.2 57.7
MGFA clinical classification (%)
Class I 23.2 9.3##
Class II 46.8 36.5#
Class III 18.7 31.4##
Class IV 4.4 8.7
Class V 6.9 14.1##




AChR-Ab-positivity (%) 81.8 (166/203) 80.4 (251/312)
MuSK-Ab-positivity (%) 3.0 1.9
*P < 0.0001 (Mann–Whitney U-test); #P < 0.05, ##P < 0.01 (v2-test) com-
pared with patients without calcineurin inhibitors (CNI). AChR-Ab,
anti-acetylcholine receptor antibodies; MG, myasthenia gravis; MGFA,
Myasthenia Gravis Foundation of America; MuSK-Ab, anti-muscle-specific
receptor tyrosine kinase antibodies; PSL, prednisolone; QMG, Myasthenia
Gravis Foundation of America quantitative myasthenia gravis score.
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status (i.e. pharmacological remission [PR] and com-
plete stable remission [CSR]) were considered a
favorably improved status, and achieving MM or
better status with oral prednisolone (PSL) ≤5 mg/day
(MM or better-5 mg) was identified as a treatment
target.4,19,21 Use of this category grouping into MM
or better and the cut-off of PSL dose at 5 mg/day
were repeatedly confirmed by analyses of clinical
data from the Japan MG Registry and the East Japan
MG study.3,4,19–21 Thus, the frequency of patients
achieving MM or better-5 mg was shown in the
present study. The worst condition for each patient
was classified according to the MGFA classification.23
Current dose, maximum dose, total dose during the
last year of PSL and the period taking ≥20 mg of PSL
were recorded. The duration between onset and
starting immune treatments (with PSL in 92.2%,
with CNI in 7.8% of the patients) and duration up
to CNI use after starting immune treatments were
obtained from medical records. MG was classified
into three subtypes as follows: early-onset MG (age
at onset ≤49 years), late-onset MG (age at onset
≥50 years) or thymoma-associated MG.2,3
Serum AChR-Ab titers were estimated by radioim-
munoassay using 125I-a-bungarotoxin, and levels
≥0.5 M were regarded as positive. MuSK-Ab was
measured using a commercially available radioim-
munoprecipitation assay (RSR, Cardiff, UK).
Statistical analysis
Differences between two groups were evaluated
using the Mann–Whitney U-test for continuous vari-
ables and the v2-test for categorical variables. All
continuous data are expressed as the mean  stan-
dard deviation. Statistical analyses were carried out
using UNISTAT version 5.6 (Unistat, London, UK) sta-
tistical software.
Results
Comparison of patients receiving immune treatments
with and without CNI regarding baseline severity,
treatment course and current status
CNI were given to severely ill MG patients in Japan
Baseline severity and other characteristics of both
patient groups are shown in Table 1. The patient
group treated with CNI had a lower frequency of
MGFA clinical classifications class I and II, a higher
frequency of class III–V and higher QMG at the
worst clinical condition, compared with the group
not treated with CNI (Table 1). CNI were apparently
given to patients with severe MG symptoms. The
frequency of thymoma-associated MG was higher in
the group taking CNI (Table 1), which probably
reflects the fact that thymoma-associated MG often
involves severe symptoms.3 It is known that MG
patients at the early stages of disease respond well to
CNI.24 However, in the present participants, the
mean duration before CNI use after starting immune
treatment was 4.4  6.3 years, suggesting that CNI
were not often used for early-stage patients. Age,
age at onset, time since onset, duration between
onset and starting immune treatments, frequency of
early-onset and late-onset MG, and frequency of
AChR- or MuSK-Ab positivity were not different
between the two groups. Patients having a higher
age at onset are more susceptible to CNI; however,
CNI were not often used for patients with higher age
at onset.24
No significant difference in baseline severity and
other characteristics was noted between patients
treated with cyclosporine (107/312, 34.3%) and
those treated with tacrolimus (205/312, 65.7%).
Patients treated with CNI remained in an unfavorable
condition
The treatment course and current status of both
patient groups are shown in Table 2. The patient
group treated with CNI currently had higher QMG,
higher MG-QOL15-J (i.e. worse HRQOL), and a
Table 2 Comparison of patients receiving immune treatments with and







Current QMG 5.7  4.4 8.1  5.6***
Current MG-QOL 15-J 11.0  10.5 16.6  14.0***
Current dose of PSL (mg/day) 4.9  6.2 5.8  5.9*
Maximum dose of PSL
(mg/day)
28.1  19.6 26.1  19.3
Total dose of PSL during
the last 1 year (mg)
1581.4  1666.4 2145.5  2079.90**
Duration of PSL ≥20
mg/day (years)
0.8  1.6 1.1  3.1
PP and/or IVIg (%) 21.2 52.6###
Achieved 5 mg-MM or
better (%)
44.8 32.4##
*P < 0.05, **P < 0.01, ***P < 0.0001 (Mann–Whitney U-test); ##P < 0.01,
###P < 0.0001 (v2-test) compared with patients without calcineurin
inhibitors (CNI). IVIg, intravenous immunoglobulin; MG, myasthenia gra-
vis; MG-QOL15-J, Japanese version of the 15-item myasthenia gravis-
specific quality of life scale; MM, minimal manifestations; PP, plasmaphe-
resis; PSL, prednisolone; QMG, Myasthenia Gravis Foundation of America
quantitative myasthenia gravis score; QOL, quality of life.
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higher daily dose and 1-year total dose of PSL,
despite equivalent levels of maximum PSL dose and
duration of PSL ≥20 mg/day, compared with the
group not treated with CNI (Table 2). The frequency
of patients who achieved MM or better-5 mg (a
treatment target) was not high in either group, and
was lower in the group treated with CNI (32.4% vs
44.8%; Table 2).
No significant difference in the treatment course
and current status was noted between patients trea-
ted with cyclosporine and those treated with tacroli-
mus, which is consistent with a previous report that
the effects of the two drugs on MG were almost
identical.24
Patients with CNI remain in an unfavorable
condition, possibly because of a strong bias favoring
CNI use for severe and intractable MG. Regrettably,
no positive correlation of CNI use to good outcome
(e.g. achieving MM or better-5 mg, or lower current
QMG or MG-QOL15-J) was detected.
Comparisons of treatment course and current status
among three MG subtypes
In the patient group receiving immune treatments with
CNI, late-onset MG achieved a more favorable current
condition than did the other two MG subtypes
When analyzing the patient group receiving immune
treatments with CNI, both current QMG and
MG-QOL15-J were lower (i.e. lower severity and bet-
ter HRQOL) for late-onset MG patients than for early-
onset and thymoma-associated MG patients (Table 3).
The frequency of patients who achieved MM or
better-5 mg was higher among late-onset MG patients
than those having the other two subtypes (Table 3).
Maximum dose, current dose and 1-year total dose of
PSL, and duration of PSL ≥20 mg/day were also lower
for late-onset MG than others (Table 3).
In the patient group receiving immune treatments with-
out CNI, there were no differences in current severity,
HRQOL and the rate of MM or better-5 mg among the
three MG subtypes
In the patients not treated with CNI, current QMG,
current MG-QOL15-J and frequency of patients
achieving MM or better-5 mg were not different
among the three MG subtypes (Table 4), in contrast
to the patients treated with CNI (Table 3). Maxi-
mum dose, current dose and 1-year total dose of
PSL, and duration of PSL ≥20 mg/day were lower
for late-onset MG patients than the others (Table 4),
which is consistent with the results of patients trea-
ted with CNI (Table 3).
Discussion
There is no doubt that CNI are generally effective for
MG, but responders to the drugs comprise <70% of
MG patients, at least at the dosage approved under
the Japanese national health insurance system.11–17,24
There are some characteristics of responder MG
patients to CNI therapy, such as higher age at onset,
Table 3 Among patients treated with calcineurin inhibitors, comparison of early-onset, late-onset and thymoma-associated myasthenia gravis groups







MG (n = 83)
Time since onset (years) 12.8  11.4 6.2  4.4***## 9.7  7.4
Current QMG 9.3  5.9 6.6  4.9* 7.9  5.2
Current MG-QOL 15-J 19.0  15.4 13.6  12.4*# 16.8  12.8
Current dose of PSL (mg/day) 6.1  6.0 5.0  6.0# 6.2  5.7
Total dose of PSL during
the last 1 year (mg)
2166.6  1971.5 1738.6  1836.3# 2626.5  2409.0
Maximum dose of PSL (mg/day) 27.4  18.8 21.5  17.4**### 35.6  16.8
Duration of PSL ≥20 mg/day (years) 1.5  3.6 0.3  0.5***### 1.6  3.8
PP and/or IVIg (%) 52.3 44.6## 62.7
Achieved 5 mg-MM or better status (%) 25.8 40.6*# 30.1
*P < 0.05, **P < 0.01, ***P < 0.0001 (Mann–Whitney U-test or v2-test) compared with early-onset myasthenia gravis (MG) patients; #P < 0.05,
##P < 0.01, ###P < 0.0001 (Mann–Whitney U-test or v2-test) compared with thymoma-associated MG patients. CNI, calcineurin inhibitors; IVIg, intrave-
nous immunoglobulin; MG, myasthenia gravis; MG-QOL15-J, Japanese version of the 15-item myasthenia gravis-specific quality of life scale; MM, mini-
mal manifestations; PP, plasmapheresis; PSL, prednisolone; QMG, Myasthenia Gravis Foundation of America quantitative myasthenia gravis score; QOL,
quality of life.
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early stages of disease and/or thymoma-associated dis-
ease.24 However, in the present participants, CNI were
given to patients with severe symptoms, but not
necessarily to those more likely to respond, probably
because the use was limited to poor-responder
patients to oral steroids under the national health
insurance up to 2009. Even currently, patients with
CNI, compared with those without CNI, showed
higher severity and worse HRQOL despite taking
more than equivalent levels of PSL during the
course of treatments. Naturally, this patient group
would have had a much more unfavorable status if
they had not taken CNI. However, it is also true that
CNI therapy, in the way presently administered, has
failed to exert a strong impact with regard to ensur-
ing favorable disease status and HRQOL for MG
patients. When a patient is recognized to not have a
good response to CNI, combination therapy with
high-dose intravenous methylprednisolone, plasma-
pheresis and/or intravenous immunoglobulin should
be started earlier. Even if the oral PSL dose is
increased, longer treatment with a higher oral PSL
dose not ensure a better outcome for intractable MG
patients.21
Higher age of MG onset is one of the susceptibility
factors for CNI therapy.24 Consistently, in the group
treated with CNI, late-onset MG patients, compared
with the other MG subtypes, achieved less severe
disease and better HRQOL despite lower levels of
PSL dosage. Such better outcome in late-onset MG
was not observed in the group without CNI, but pos-
sibly could have been achieved if CNI had been
given. In other words, these late-onset MG patients
could have achieved better outcome than the pres-
ent results if with CNI. Furthermore, MG patients in
early stages of the disease are known to be suscepti-
ble to CNI, but the drugs were not often used for
such patients.24 Achieving a treatment target (MM
or better-5 mg) was also not frequent enough in the
patient group treated without CNI (44.8%), even
with their lower baseline severity. Considering these
present and previously reported findings, it is better
to given CNI more aggressively to patients having
susceptibility factors to the drugs, such as higher
agse at onset and the early stages of disease, regard-
less of baseline severity.24
Thymoma-associated MG patients are known to
have a larger reduction in severity in response to
CNI, and were more frequently included in the
patient group treated with CNI.24 However, thymo-
ma-associated MG is the most severe subtype at
worst condition, and requires the most aggressive
immune treatment of the three MG subtypes, thus
the higher frequency of this subtype in the CNI
group in and of itself would not necessarily lead to a
more favorable overall outcome.3 The doses of CNI
used for MG treatment are often lower and thus
safer than those used for preventing organ rejection
in clinical organ transplantation, which could be one
of the reasons why CNI therapy failed to exert a
strong impact on the MG population.
In conclusion, CNI were given to MG patients
with severe symptoms with no attempt to select
those more likely to respond, and thus failed to exert
Table 4 Among patients not treated with calcineurin inhibitors, comparison of early-onset, late-onset and thymoma-associated myasthenia gravis







MG (n = 37)
Time since onset (years) 15.8  12.6 7.2  5.9**# 11.3  9.5
Current QMG 5.5  4.1 5.7  4.7 6.5  4.7
Current MG-QOL 15-J 10.1  4.0 11.8  11.9 11.4  8.9
Current dose of PSL (mg/day) 4.9  6.1# 3.5  4.2# 7.7  8.7
Total dose of PSL during the last 1 year (mg) 1649.7  1834.7 1247.9  1206.5# 2044.0  1876.4
Maximum dose of PSL (mg/day) 32.3  17.3 24.7  19.4*# 35.1  20.2
Duration of PSL ≥20 mg/day (years) 0.9  1.1 0.4  1.2**## 1.2  2.7
PP and/or IVIg (%) 22.2 10.5*### 40.5
Achieved 5 mg-MM or better status (%) 45.6 (41/90) 51.3 (39/76) 37.8 (14/37)
*P < 0.05, **P < 0.0001 (Mann–Whitney U-test or v2-test) compared with early-onset myasthenia gravis (MG) patients; #P < 0.05, ##P < 0.01,
###P < 0.0001 (Mann–Whitney U-test or v2-test) compared with thymoma-associated MG patients. CNI, calcineurin inhibitors; IVIg, intravenous immuno-
globulin; MG, myasthenia gravis; MG-QOL15-J, Japanese version of the 15-item myasthenia gravis-specific quality of life scale; MM, minimal manifesta-
tions; PP, plasmapheresis; PSL, prednisolone; QMG, Myasthenia Gravis Foundation of America quantitative myasthenia gravis score; QOL, quality of life.
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a strong impact on MG therapy. As the frequency of
CNI use was not high, CNI should be given more
aggressively to patients with higher age at onset and
in the early stages of disease, regardless of baseline
severity.
Acknowledgements
We thank Dr S. Ohji and Dr K. Nomura (Saitama
Medical Center), Dr E. Tsuda (Sapporo Medical Uni-
versity Hospital), and Dr S. Nakane (Nagasaki Kawa-
tana Medical Center) for the collection of patient
data. This work was supported by the Japan MG reg-
istry group and funded by Astellas Pharmaceutical
under the sponsored research contact. Astellas Phar-
maceutical had no role in the study design, data col-
lection and analysis, decision to publish, or




1. Patrick J, Lindstrom J. Autoimmune response to acetyl-
choline receptor. Science. 1973; 180: 871–2.
2. Meriggioli MN, Sanders DB. Autoimmune myasthenia
gravis: emerging clinical and biological heterogeneity.
Lancet Neurol. 2009; 8: 475–90.
3. Murai H, Masuda M, Utsugisawa K, et al. Clinical features
and treatment status of adult myasthenia gravis in
Japan. Clin Exp Neuroimmunol. 2014; 5: 84–91.
4. Utsugisawa K, Suzuki S, Nagane Y, et al. Health-related
quality of life and treatment targets in myasthenia gra-
vis. Muscle Nerve. 2014; 50: 493–500.
5. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoan-
tibodies to low-density lipoprotein receptor-related pro-
tein 4 in myasthenia gravis. Ann Neurol. 2011; 69: 418–22.
6. Fujii Y, Lindstrom J. Regulation of antibody production
by helper T cell clones in experimental autoimmune
myasthenia gravis. J Immunol. 1988; 141: 3361–9.
7. Mokhtarian F, Pino M, Ofosu-Appiah W, Grob D. Pheno-
typic and functional characterization of T cells from
patients with myasthenia gravis. J Clin Invest. 1990; 86:
2099–108.
8. Kino T, Hatanaka H, Miyata S, et al. FK506, a novel
immunosuppressant isolated from a streptomyces. II.
Immunosuppressive effect of FK506 in vitro. J Antibiot
(Tokyo). 1987; 40: 1256–65.
9. Schreiber SL, Crabtree GR. The mechanism of action of
cyclosporin A and FK506. Immunol Today. 1992; 13: 136–
42.
10. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL.
Cyclosporin; An updated review of the pharmacokinetic
properties, clinical efficacy and tolerability of a micro-
emulsion-based formulation (Neoral) in organ trans-
plantation. Drug. 2001; 61: 1957–2016.
11. Utsugisawa K, Nagane Y, Suzuki S, Suzuki N. Monitoring
treatment with cyclosporine microemulsion in myasthe-
nia gravis. Eur J Neurol. 2008; 15: 598–604.
12. Tindall RSA, Rollins JA, Phillips JT, Greenlee RG, Wells L,
Belendiuk G. Preliminary results of a double-blind, ran-
domized, placebo-controlled trial of cyclosporine
in myasthenia gravis. N Engl J Med. 1987; 316: 719–24.
13. Ciafaloni E, Nikhar NK, Massey JM, Sanders DB. Retro-
spective analysis of the use of cyclosporine in myasthe-
nia gravis. Neurology. 2000; 55: 448–50.
14. Evoli A, Di Schino C, Marsili F, Punzi C. Successful treat-
ment of myasthenia gravis with tacrolimus. Muscle
Nerve. 2002; 25: 111–4.
15. Konishi T, Yoshiyama Y, Takamori M, Saida T. Long-term
treatment of generalised myasthenia gravis with FK506
(tacrolimus). J Neurol Neurosurg Psychiatry. 2005; 76:
448–50.
16. Nagane Y, Utsugisawa K, Obara D, Kondoh R, Terayama
Y. Efficacy of low-dose FK506 in the treatment of myas-
thenia gravis-A randomized pilot study. Eur Neurol. 2005;
53: 146–50.
17. Yoshikawa H, Kiuchi T, Saida T, Takamori M. Rando-
mised, double-blind, placebo-controlled study of tacroli-
mus in myasthenia gravis. J Neurol Neurosurg Psychiatry.
2011; 82: 970–7.
18. Gilhus NE. Autoimmune myasthenia gravis. Expert Rev
Neurother. 2009; 9: 351–8.
19. Masuda M, Utsugisawa K, Suzuki S, et al. The MG-QOL15
Japanese version: validation and associations with clini-
cal factors. Muscle Nerve. 2012; 46: 166–73.
20. Suzuki Y, Utsugisawa K, Suzuki S, et al. Factors associ-
ated with depressive state in patients with myasthenia
gravis: a multicenter cross-sectional study. BMJ Open.
2011; 1: e000313.
21. Imai T, Suzuki S, Tsuda E, et al. Oral corticosteroid ther-
apy and present disease status in myasthenia gravis.
Muscle Nerve. 2015; doi: 10.1002/mus.24438.
22. Grob D, Brunner N, Namba T, Pagala M. Lifetime
course of myasthenia gravis. Muscle Nerve. 2008; 37:
141–9.
23. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. for the Task
Force of the Medical Scientific Advisory Board of Myas-
thenia Gravis Foundation of America. Myasthenia gravis:
recommendations for clinical research standards. Neurol-
ogy. 2000; 55: 16–23.
24. Nagane Y, Suzuki S, Suzuki N, Utsugisawa K. Factors
associated with response to calcineurin inhibitors in
myasthenia gravis. Muscle Nerve. 2010; 41: 212–8.
© 2015 Japanese Society for Neuroimmunology200
CNI treatment of MG in Japan K. Utsugisawa et al.
